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ABSTRACT
The cytochrome P450 metabolites of arachidonic acid (AA) are mostly present in tissues, such as
the liver, as bound to phospholipids, with only a small fraction available as free acids. The
purpose of this study was to develop and validate a UHPLC-MS/MS method for quantitation of
free liver concentrations of AA and four epoxygenated (5,6-, 8,9-, 11,12-, and 14,15-EET), four
dihydroxylated (5,6-, 8,9-, 11,12-, and 14,15-DHET), and two ω/(ω-1) hydroxylated (19- and 20HETEs) metabolites of AA in rat livers using deuterated internal standards. The analytes were
rapidly and efficiently (79-92%) recovered from 100 mg of fresh liver into methanol. After
evaporation, the reconstituted samples were injected either undiluted (for the simultaneous
analysis of the metabolites) into a gradient or diluted (for AA analysis) into an isocratic UHPLC
system with run times of 5 and 2 min, respectively. Mass spectrometry was conducted using
multiple reaction monitoring in negative mode. The method was linear (r2≥0.98) in the
concentration ranges tested for metabolites (0.19-120 ng/g liver) and AA (7.8-500 µg/g liver).
The lower limit of quantitation of the assay was between 0.57 to 5.6 pg injected on column for
different AA metabolites. The assay was validated (n = 5) based on acceptable intra- and interrun accuracy and precision values. Additionally, matrix effect was minimal for most analytes.
Freeze-thaw of samples drastically increased the free liver concentrations of analytes,
presumably due to their release from the membrane storage sites. Therefore, fresh liver samples
should be used for analysis. However, the methanolic extracts may be stored at -80oC for at least
two weeks without any compromise. The method was successfully used in the measurement of
all the analytes in the rats subjected to 60 min of hepatic ischemia (n = 6) or sham operation (n =
6). Ischemia resulted in significantly higher free concentrations of AA and most of its studied
metabolites. The method is precise, accurate, and sensitive for measurement of free liver
concentrations of AA and its P450 metabolites in the rat liver.
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1. Introduction
Arachidonic acid (AA), or 5,8,11,14-eicosatetraenoic acid, is a polyunsaturated omega-6
fatty acid that is abundantly present in the phospholipids of cellular membranes. AA is released
from membranes upon hydrolysis of the sn-2 fatty acyl bond of phospholipids by activation of
calcium dependent type IV phospholipase A2 in response to stimulus [1, 2]. The released AA can
be subsequently metabolized by three different groups of enzymes, namely cyclooxygenases,
lipoxygenases, and cytochromes P450 (P450) [2-5]. Whereas the cyclooxygenase enzyme
converts AA to prostaglandins and thromboxane A2, the products of AA metabolism by
lipoxygenase are 5-, 8-, 12-, and 15-hydroxyeicosatetraenoic acids (HETEs) and leukotrienes [5].
The more recently-discovered metabolic pathway catalyzed by P450 enzymes [6-8] includes
epoxygenation of AA to four regioselective epoxyeicosatrienoic acids (EETs) and ω/(ω-1)
hydroxylation to two major hydroxylated metabolites 19- and 20-HETE (Fig. 1) in addition to
other regioselective hydroxylated metabolites. Similar to AA, EETs are also extensively
incorporated into the sn-2 position of phospholipids, and only a small fraction of EETs (< 1%)
are in the form of free acids in the tissues [9, 10]. Additionally, EETs are further metabolized by
soluble epoxide hydrolase (sEH) to dihydroxyeicosatrienoic acids (DHETs) (Fig. 1) [10].
Therefore, the concentrations of free EETs in tissues are very low [9].
Both hydroxylated and epoxygenated P450 metabolites of AA are known to be potent
regulators of vascular tone. For example, in coronary circulation, it is believed that HETEs
(mainly 20-HETE) act as vasoconstrictors [11], whereas EETs act as vasodilators [12]. However,
these effects may be tissue dependent because 20-HETE induces medullary vasodilation in the
kidneys [13]. Because of their effects on the vascular tone, and possibly other cellular events,
EETs and HETEs play a significant role in the pathophysiology of different diseases, such as

	
  

4	
  

ischemia-reperfusion (IR) injury [14] and portal hypertension [15]. Therefore, it is necessary to
study the disposition and effects of P450-mediated metabolites of AA in different diseases.
The study of the disposition of the P450-mediated metabolites of AA requires
sophisticated analytical methods capable of simultaneous quantitation of regioselective isomers
of epoxygenated (EETs), hydroxylated (HETEs), and dihydroxylated (DHETs) metabolites with
very low free concentrations in the plasma and tissues. In the past, techniques like gas
chromatography-mass spectrometry (GC-MS) [16, 17], liquid chromatography (LC) with
fluorescence detection [18, 19], LC-mass spectrometry (LC-MS) [20, 21], and LC-tandem mass
spectrometry (LC-MS/MS) [22-24] were used to measure the free concentrations of some EETs,
HETEs, or DHETs in plasma or tissue samples. Among these methods, LC-MS/MS has the
highest potential in this area due to its high specificity and sensitivity for simultaneous
quantitation of a wide range of structurally similar analytes, such as structural isomers of
eicosanoids, within a single run [25]. However, to the best of our knowledge, a validated LCMS/MS method for quantitation of free concentrations of EETs, HETEs, and DHETs in the liver
tissue is not yet available. Such a method is especially important because despite the fact that the
liver is the major site of P450 enzymes in the body, the disposition and effects of P450-mediated
AA metabolites in the liver are largely unknown. Therefore, the objective of the current study
was to develop and validate an accurate, sensitive, and reproducible method to simultaneously
measure the free concentrations of AA and its major P450 metabolites in the liver matrix.
Additionally, the method was successfully applied to evaluation of the effects of hepatic
ischemia on the free liver concentrations of AA and its P450 metabolites in rats.
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2. Materials and methods
2.1. Chemicals
The following standards were purchased from Cayman Chemical Company (Ann Arbor,
MI): 5Z,8Z,11Z,14Z-eicosatetraenoic acid or AA, 19-(R)-hydroxyeicosatetraenoic acid (19HETE), 20-hydroxyeicosatetraenoic acid (20-HETE), (±)-5,6-epoxyeicosatrienoic acid (5,6EET),	
  (±)-8,9-epoxyeicosatrienoic acid (8,9-EET), (±)-11,12-epoxyeicosatrienoic acid (11,12EET), (±)-14,15-epoxyeicosatrienoic acid (14,15-EET), (±)-5,6-dihydroxyeicosatrienoic acid
(5,6-DHET), (±)-8,9-dihydroxyeicosatrienoic acid (8,9-DHET), (±)-11,12dihydroxyeicosatrienoic acid (11,12-DHET), and (±)-14,15-dihydroxyeicosatrienoic acid (14,15DHET). Additionally, the following deuterated internal standards (IS) were also obtained from
the same company: 20-HETE-d6 (deuterium atoms at the 16, 16', 17, 17', 18, and 18' positions;
isotopic purity of ≥99%), 8,9-EET-d11 (deuterium atoms at the 16, 16', 17, 17', 18, 18', 19, 19',
20, 20, and 20 positions; isotopic purity of ≥99%), 14,15-EET-d11 (deuterium atoms at the 16,
16', 17, 17', 18, 18', 19, 19', 20, 20, and 20 positions; isotopic purity of ≥99%), 14,15-DHET-d11
(deuterium atoms at the 16, 16’, 17, 17’, 18, 18’, 19, 19’, 20, 20, and 20 positions; isotopic purity
of ≥99%), and AA-d8 (deuterium atoms at the 5, 6, 8, 9, 11, 12, 14, and 15 positions; isotopic
purity of ≥99%). LC-MS grade water was purchased under the brand name J.T. Baker from
Avantor Performance Materials, Inc. (Center Valley, PA). HPLC grade glacial acetic acid and
LCMS grade acetonitrile were purchased from Fisher Scientific (Fair Lawn, NJ). All other
reagents used were also of HPLC grade and purchased through commercial sources.
2.2. UHPLC-MS/MS instrumentation
The UHPLC-MS/MS instrument consisted of an AB SCIEX QTRAP® 5500 mass
spectrometer (Foster City, CA, USA) attached to a Nexera UHPLC system from Shimadzu
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Corporation (Columbia, MD). The UHPLC system consisted of a Sil-30AC autosampler, LC30AD pumps, a CBM-20A controller, a DGA-20A5 degasser, and a CTO-30A column oven.
Analyst and MultiQuant software were used for data acquisition and quantitation, respectively.
2.3.Chromatographic conditions
The chromatographic separation of analytes was performed at 40oC on a Kinetex C18
column (5 cm x 2.10 mm I.D., 1.7 µm particle size, 100Å pore size), preceded by a
SecurityGurad ULTRA guard column (Phenomenex; Torrance, CA, USA). The elution of all the
analytes, except for AA and AA-d8, was based on a gradient method using mobile phases of
water: acetonitrile: acetic acid (95:5:0.005, v/v/v) (A) and acetonitrile: acetic acid (100:0.005,
v/v) (B), which was run at a flow rate of 0.5 mL/min. The elution started with 50% B, which was
increased to 60% B over 2 min and kept constant until 3.2 min. At 3.2 min, the mobile phase was
switched to 100% B and maintained until 4 min, which was followed by return to the initial
condition. The total run time was 5 min, but the mass spectrometer data was collected only from
0.4 to 3.1 min. For AA and AA-d8, an isocratic mobile phase of A:B (20:80, v/v) was used at a
flow rate of 0.5 mL/min for 2 min. The mass spectrometer data here was collected from 0.3 to
1.5 min. The injection volumes used were 3 µL for all the samples because larger injection
volumes caused band broadening.
2.4. Mass spectrometric conditions
A triple quadrupole mass spectrometer was used to analyze the analytes by monitoring
their m/z transitions with the help of Analyst software. The ionization source was through
electrospray ionization (TurbolonSpray), and the analytes were detected using multiple reaction
monitoring (MRM) operated in the negative mode. The source/gas and compound parameters
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were optimized to obtain the highest [M-H]- ion abundance by infusing the standard solutions of
the analyte of interest via a syringe pump into the mass spectrometer. The optimized source/gas
parameters were as follows: curtain gas, 35 psi; collision gas, high; ion spray voltage, -4500 V,
temperature, 6500C, ion source gas 1 (nebulizer gas), 60 psi; and ion source gas 2 (turbo gas), 60
psi. The compound parameters were optimized for each of the analytes and are represented in
Table 1. For most of the analytes, the product ions selected in our study (Table 1) are similar to
those reported previously [25, 26].
2.5. Preparation of stock solutions, calibration standards, and quality control samples
All the stock solutions were prepared in ethanol and stored at -80oC. The stock solution
of metabolites consisted of 60 ng/mL of 19-HETE, 20-HETE, and 11,12-DHET; 48 ng/mL of
8,9-EET and 8,9-DHET; 24 ng/mL of 5,6-EET, 11,12-EET, 14,15-EET, and 5,6-DHET; and 240
ng/mL of 14,15-DHET. The stock solution of IS for the metabolites contained 60 ng/mL of 20HETE-d6 (for 19-HETE and 20-HETE), 50 ng/mL of 8,9-EET-d11 (for 8,9-EET and 11,12-EET),
50 ng/mL of 14,15-EET-d11 (for 5,6-EET and 14,15-EET), and 120 ng/mL of 14,15-DHET-d11
(for 5,6-DHET, 8,9-DHET, 11,12-DHET, and 14,15-DHET). Calibration standards were then
prepared by diluting the metabolite stock solution in ethanol before the addition of an equal
volume of the IS solution. The resulting calibration standards ranged from 0.94-30 ng/mL for 19HETE and 20-HETE; 0.48-30 ng/mL for 11,12-DHET; 0.75-24 ng/mL for 8,9-EET; 0.38-24
ng/mL for 8,9-DHET; 0.38-12 ng/mL for 5,6-EET, 11,12-EET, and 14,15-EET; 0.19-12 ng/mL
for 5,6-DHET; and 1.88-120 ng/mL for 14,15-DHET. A separate stock solution of AA consisting
of 1000 µg/mL was prepared in ethanol. Calibration standards for AA were then prepared by
diluting the stock solution with ethanol before mixing each standard with an equal volume of the
IS solution (140 µg/mL of AA-d8). The resulting calibration standards for AA ranged from 7.81
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to 500 µg/mL. Calibration curves were constructed by plotting the analyte: IS peak area ratios
(y) against the concentration of each analyte (x) using a weight of 1/concentration. The unknown
concentrations of analytes in the reconstituted final solution (ng/mL) injected into the instrument
were then estimated from the calibration curve. Because in our studies we used 100 mg of liver
and reconstituted the final residue in 100 µL of ethanol before injection (section 2.6), the
estimated concentration in the reconstituted solution (ng/mL) was assumed to be the
concentration in the liver tissue (ng/g).
Quality control (QC) samples were prepared in ethanol using the highest and lowest
concentrations used in the calibration curves plus a third sample in the middle of the calibration
curves (eight fold lower than the highest standard). These concentrations were 30, 3.75, and 0.94
ng/mL for 19-HETE and 20-HETE; 12, 1.5, and 0.38 ng/mL for 5,6-EET, 11,12-EET, and 14,15EET; 24, 3, and 0.75 ng/mL for 8,9-EET; 12, 1.5, and 0.19 ng/mL for 5,6-DHET; 24, 3, 0.38
ng/mL for 8,9-DHET; 30, 3.75, and 0.48 ng/mL for 11,12-DHET; 120, 15, and 1.88 ng/mL for
14,15-DHET; and 500, 62.5, and 7.81 µg/mL for AA.
2.6. Sample preparation
After addition of 950 µL of ice-cold 0.01 M BHT in methanol, fresh liver samples (100
mg) were homogenized using a glass/PTFE Potter Elvehjem tissue grinder for 15 s.
Subsequently, 50 µL of the IS solution was added to the homogenate, and the samples were
vortex-mixed for 5 s and centrifuged at 19,500 x g for 15 min at 0oC. The resultant supernatant
was transferred to a silanized glass tube and dried under nitrogen gas. The dried residue was
reconstituted in 100 µL of ethanol, vortex-mixed for 15 s, and subjected to a final centrifugation
at 19,500 x g for 15 min at 0oC. The resultant supernatant was divided into two parts for separate
analysis of AA and the rest of the analytes. For the AA analysis, 10 µL of the supernatant was
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diluted 4000 fold before injection into the UHPLC-MS/MS. The rest of the supernatant was
used directly without dilution for the analysis of the other analytes. The injection volume was 3
µL in both cases.
2.7. Method validation
Intra- and inter-run accuracy and precision of the method were evaluated based on the
analysis of QC samples, along with calibration standards, at low, middle, and high analyte
concentrations (n = 5). Accuracy was calculated using the following equation:
!""#$%"&! % =

!"#$%&"'!!"#$%#&'(&)"#
×100!
!"#$%&'!!"#$%#&'(&)"#

Precision was estimated as percentage relative standard deviation (R.S.D.). The acceptable limits
for accuracy were 85%-115% for the middle and high concentrations and 80%-120% for the low
concentration. The acceptable precision was ≤ 15% for the middle and high concentrations and ≤
20% for the lower limit of quantitation (LLOQ).
The linearity of the method was evaluated by linear regression analysis of the calibration
curves in the ranges stated in section 2.5.
2.8. Recovery
The recoveries of AA, metabolites, and internal standards from the liver homogenates
were estimated by comparison of detector response to the processed liver homogenates
(Baseline, n = 6), homogenates spiked with known quantities of the analytes before processing
(Test, n = 6), and processed homogenates that were spiked with equivalent quantities of the
analytes during the final reconstitution of the extracts (Control, n = 6). The recovery experiments
were conducted at equivalent liver concentrations (spiked) of 15 ng/g of 19-HETE and 20-
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HETE; 12 ng/g of 5,6-EET; 6 ng/g of 8,9-EET, 11,12-EET, 14,15-EET, 11,12-DHET, and
14,15-DHET; 24 ng/g of 5,6-DHET and 8,9-DHET; and 500 µg/g of AA. The liver samples were
spiked with the analytes after homogenization in methanol. The recoveries of internal standards
were estimated at the concentrations that they were used in the assay. The following equation
was used for the estimation of recoveries:
!"#$%"&'! % =

!"#$ !"#$ − !"#$!"#$%&'$
×100!
!"#$!"#$%"& − !"!"!"#$%&'$

where AreaTest, AreaControl, and AreaBaseline are the peak areas of Test, Control, and Baseline
samples, respectively. The AreaBaseline for the deuterated internal standards were zero.
2.9. Matrix effect
Duplicate liver samples from six different rats were extracted into methanol, and the
supernatants were evaporated. One set of samples was processed normally by dissolving the
residues in 100 µL of ethanol without analyte spiking (Baseline), whereas the other set was
reconstituted in ethanol spiked with known quantities of the analytes (Matrix). Additionally,
equivalent concentrations of analytes in ethanol (Standard) were directly injected into the
UHPLC system without addition to any sample residue. The matrix factor (MF) was then
calculated according to the following equation:
!"! % =

!"#$!"#$%& − !"#$!"#$%&'$
×100!
!"#$!"#$%#&%

where AreaMatrix, AreaBaseline, and AreaStandard are the peak areas of Matrix, Baseline
(endogenous), and Standard samples, respectively. The AreaBaseline for the deuterated internal
standards was zero. Using the above equation, MF values less than 100% indicate ion
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suppression, values greater than 100% indicate ion enhancement, and values equal to 100%
indicate no matrix effect.
2.10.

Effects of sample handling on the liver concentrations of AA and its metabolites
Rat liver samples were subjected to the Sample preparation procedure described in

section 2.6 immediately after collection (Fresh-0), after 20 (Fresh-20), 40 (Fresh-40), or 60
(Fresh-60) min of storage on ice, or after snap-freezing in nitrogen and thawing (20 min). The
effects of sample handling method on the concentrations of AA and its metabolites were then
determined (n =3-4).
2.11.

Stability of the methanolic extracts of the processed fresh liver samples at -80oC
The stability of the methanolic supernatants, which were obtained after homogenization

of the fresh liver samples, was studied at -80oC over a period of four weeks. Fresh liver samples
(n = 6) from Sham rats (section 2.13) were homogenized in methanol as described in section 2.6,
and the supernatants were stored at -80oC without further processing. At baseline and after 1, 2,
and 4 weeks of storage, the methanolic supernatants were further processed as described in
section 2.6 and injected into the UHPLC-MS/MS instrument.
2.12.

Sample stability in the Autosampler
The autosampler stability (4oC) of AA, its metabolites, and internal standards in the

processed liver samples (n = 4) was tested by injecting the samples into the UHPLC-MS/MS
immediately (time zero) or after 1, 3, or 5 h of storage in the autosampler. The stability was
evaluated by examining the absolute peak areas of the analytes and internal standards in addition
to the analyte: IS peak area ratios after different autosampler storage times.
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2.13.

Application of the method
The method was used to study the effects of injury from partial (70%) hepatic ischemia

(Ischemia) on the concentrations of AA and its metabolites in the rat livers. Adult male SpragueDawley rats (body weights ranging from 250-300 g) were purchased from Charles River
Laboratories, Inc. (Wilmington, MA, USA) and maintained on a 12 h light/dark cycle in our
institutional animal facility with free access to food and water before the experiments. All the
procedures were in compliance with the guidelines set by the National Institutes of Health (NIH
publication #85-23, revised 1985) and were approved by our Institutional Animal Care and Use
Committee. The surgical procedures were similar to those published earlier [27, 28]. Briefly,
after an overnight fast, animals were anesthetized using an intramuscular injection of ketamine:
xylazine (80:10 mg/kg). Ischemia (n = 6) was induced by occluding the portal triad (portal vein,
hepatic artery, and bile duct) connected to the left and median lobes of the liver for 60 min,
leaving the blood supply to the right and caudate lobes uninterrupted. Sham-operated rats (n = 6)
underwent the same procedure, except for clamping the portal triad. During the ischemic period,
the body temperature of the rats was maintained at 37oC using a heating platform and lamp. At
the end of the ischemic period, liver was perfused with cold saline and immediately
homogenized in methanol containing 0.01 M BHT and internal standards. The resultant
supernatant was separated and stored at -80oC until analysis within one week.
2.14.

Statistical analysis
The data for the stability of final samples in the autosampler and stability of the

methanolic extracts in the freezer were analyzed by repeated-measure, one-way ANOVA.
Ordinary, one-way ANOVA was used for the analysis of the effects of sample handling on the
final results. In both cases, post-hoc analysis of means was carried out using Dunnett’s multiple
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comparison test. Concentrations of the analytes in the liver samples of Sham and Ischemia
groups were compared using an unpaired, two-tailed t-test with Welch’s correction for the
differences in the variances. In all cases, a P value of < 0.05 was considered significant. The data
are presented as mean ± S.D.

3. Results
3.1. UHPLC-MS/MS
Figures 2 and 3 represent the chromatograms of standard solutions of AA metabolites and
AA, respectively, along with their internal standards. Except for 8,9-DHET, 14,15-EET, and the
14,15-EET-d11 internal standard, all the analytes showed one major peak using the MRM mode
at the selected m/z transition (Table 1) optimized for them (Fig. 2). However, at the optimized
m/z transition for 8,9-DHET (337à127), an additional peak was observed with a retention time
corresponding to 14,15-DHET, and for 14,15-EET (m/z transition of 319à219), an additional
peak was observed with a retention time corresponding to 8,9-EET (Fig. 2). Additionally, for
14,15-EET-d11, with an optimized m/z transition of 330à268, an additional peak was observed
with a retention time corresponding to the 8,9-EET-d11 internal standard (Fig. 2). These
additional peaks were due to the fact that the optimized m/z transitions selected for 8,9-DHET,
14-15-EET, and 14,15-EET-d11 were also produced by 14,15-DHET, 8,9-EET, and 8,9-EET-d11,
respectively, although with much lower abundance. Indeed, the extra peaks were absent when
8,9-DHET, 14,15-EET, or 14,15-EET-d11 was injected alone or in the presence of all the other
analytes except for 14,15-DHET, 8,9-EET or 8,9-EET-d11 (data not shown). Nevertheless,
because of complete resolution of the extra peaks from the analytes of interest (Fig. 2), the extra
peaks did not interfere with the quantitation of these analytes. This is in agreement with a
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previous report [29] indicating that, because of similar m/z transitions, some fatty acids and
eicosanoids need to be chromatographically resolved.
Using the gradient system with an upper limit of 60% acetonitrile, described in the
Methods section, all the P450 metabolites of AA eluted within 3 min after the injection, with
DHETs eluting first, followed by HETEs and EETs (Fig. 2). Whereas the retention times of
DHETs ranged from 0.87 to 1.17 min, those of HETEs and EETs ranged from 1.17 to 1.21 and
from 2.21 to 2.54 min, respectively (Fig. 2). Additionally, the retention times of the internal
standards were close to those of their non-deuterated counterparts (Fig. 2). Using the isocratic
mobile phase, AA and its deuterated internal standard were eluted at 0.77 and 0.76 min,
respectively (Fig. 3). The inter-day (n = 5) R.S.D values for retention times were ≤ 0.8% for AA
and its IS and ≤ 0.6% for the metabolites and their internal standards.
3.2. Method validation
The standard curves, which were prepared in ethanol, were evaluated by linear regression
analysis, and the representative equations for the analytes are presented in Table 2. The
coefficient of determination (r2) for each of the analytes was ≥ 0.98, indicating satisfactory
linearity of the standard curves in the selected calibration range. Additionally, the intercept value
in the case of all analytes contributed <15% to the lowest concentration in the calibration curve.
The results of intra- and inter-run accuracy and precision evaluated by analyzing the QC
samples at low, middle, and high concentrations are presented in Table 3. The concentrations
chosen for the evaluation of accuracy and precision for different analytes were based on their
endogenous concentration range. The accuracy and precision values for all the 11 analytes were
within the acceptable range [30]. This means that the accuracy values were within 85% to 115%
for the middle and high concentrations and within 80% to 120% for the lowest concentrations
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(Table 3). Additionally, the precision values (R.S.D.) were ≤ 15% and ≤ 20% for the middle and
high concentrations and the lowest concentrations, respectively (Table 3). Based on these data,
the lowest concentrations listed in Table 3 were considered as the LLOQ of the assay for each
analyte. Based on a 3-µL injection, these concentrations translate to a range of 0.57 (for 5,6DHET) to 5.64 (for 14,15-DHET) pg on column for various metabolites of AA.
3.3. Recovery and matrix effect
The recoveries of AA, P450 metabolites, and internal standards along with the matrix
factor are reported in Table 4. Overall, the recovery values varied from 78.8% to 92.1% for all
the compounds (Table 4). Whereas the recoveries were close to 90% for AA, HETEs, DHETs,
and their corresponding internal standards, those of EETs and their internal standards were closer
to 80% (Table 4). However, within each group of analytes, the recovery of all the regioselective
isomers and internal standards were very close to each other (Table 4). 	
  
As for the matrix effect, the data in Table 4 indicate that the effects of matrix on the
detector response to most of the analytes were minimal. The highest matrix effect was observed
for 8,9-EET (MF of 82.5%) and 11,12-EET (MF of 77.1%), which was similar to the matrix
effect for their internal standard 8-9-EET-d11 (MF of 77.0%) (Table 4). Additionally, the internal
standards for AA, HETEs, and DHETs showed similar extent of ion suppression as their
respective standards (Table 4).
3.4. Effects of sample handling on the liver concentrations of AA and its metabolites
Figure 4 depicts the concentrations of AA and its metabolites in fresh liver samples that
were homogenized after being kept on ice for up to 60 min and also when the samples were
homogenized after a freeze-thaw cycle. The sample handling method had a significant (P <
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0.001) effect on the measured concentrations of the analytes. Although the short storage of the
fresh samples on ice over 60 min generally resulted in relatively modest increases in the liver
concentrations of all analytes, the increases after the freeze-thaw cycle were immense. The
magnitude of the increases in the analyte concentrations after the freeze-thaw cycle ranged from
10- (for 14,15-DHET) to 120- (for 5,6-EET) fold (Fig. 4).
3.5. Stability of the methanolic extracts at -80oC
Figure 5 depicts the effects of storage of methanolic extracts at -80oC on the
concentrations of AA and its metabolites in liver samples from six different sham-operated rats.
Except for 20-HETE and 14,15-EET, the concentrations of the analytes remained constant,
compared with the baseline values, during the entire four weeks of storage (Fig. 5). For 20HETE and 14,15-EET, the concentrations at the fourth week of storage were 13.5 % (P < 0.01)
and 18.2% (P < 0.01) lower than their baseline concentrations, respectively, but remained
unchanged for up to two weeks of storage (Fig. 5).
3.6.Stability of the processed samples in autosampler
Figure 6 demonstrates the absolute peak areas of the analytes and internal standards in
samples, prepared from four individual rat livers, after 0, 1, 3, and 5 h storage (4oC) in the
autosampler. Neither peak areas (Fig. 6) nor analyte: IS peak area ratios (data not shown) were
significantly affected by the autosampler storage for at least 5 h when the autosampler was
maintained at 4oC.
3.7. Application of the method
Figure 7 depicts the concentrations of AA and its P450 metabolites in the liver samples
collected from the animals that underwent partial hepatic ischemia or sham operation. All the 11
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analytes, for which the assay was validated, were measurable in the livers of both Sham and
Ischemia rats (Fig. 7). Additionally, except for 20-HETE (Fig. 7B), the concentrations of AA and
its P450 metabolites in the ischemic livers were significantly higher than those in the sham
groups (Fig. 7). Among the studied analytes, the highest liver concentration was observed for
AA, ranging from 75 to 223 µg/g (Fig. 7A). Comparatively, 5,6-, 8,9-, and 11,12-EET (Fig. 7C)
and 5,6-DHET (Fig. 7D) were present in very low concentrations ranging from 0.61-7.7 ng/g,
with 5,6-DHET (Fig. 7D) exhibiting the lowest concentration. In comparison to 19-HETE, 20HETE showed 1.2-4 fold higher concentration (Fig. 7B). Additionally, among EETs, 14,15-EET
showed the highest concentration (Fig. 7C). Similarly, among DHETs, the concentrations of
14,15-DHET were the highest (Fig. 7D). Indeed, among all the metabolites of AA, 14,15-DHET
showed the highest concentrations in both the Sham and Ischemia groups (Fig. 7D).

4. Discussion
Earlier analytical methods for determination of cytochrome P450 metabolites of AA were
based on gas chromatography coupled with mass spectrometry [16, 17, 31]. However, these
methods require sample derivatization before analysis and have relatively long run times. For
example, before GC-MS analysis of 20-HETE, EETs, and DHETs in dog plasma, the carboxylic
and/or hydroxyl groups of these analytes had to be derivatized in two separate steps [16]. In
recent years, LC-MS/MS method with electrospray ionization has emerged as a method of choice
for quantitation of these metabolites and other eicosanoids [22-26, 32-34] because of lack of
need for derivatization, ease of ionization, specificity, and sensitivity. However, only a limited
number of the available LC-MS/MS methods have been applied and validated for the analysis of
low concentrations of these metabolites in plasma [24] or tissues [22, 23]. The two available

	
  

18	
  

methods for tissues measure some EETs, HETEs, or DHETs in the human intrauterine tissues
[22] or human CSF and rat brain [23]. However, there is no such quantitative method available
for the determination of these metabolites in the liver, which is a major site for the P450mediated metabolism of AA [35]. Therefore, we developed and validated a sensitive method for
the simultaneous quantitation of free (i.e., not bound to phospholipids) concentrations of major
P450 metabolites of AA in the liver, which is reported here.
While it is also important to quantitate the free concentrations of AA along with its
metabolites in order to study the effects of various pathophysiological conditions on the
disposition and effects of AA metabolites, most reported LC-MS/MS methods only quantitate
the AA metabolites without quantitating AA itself. This is most likely due to the significantly
higher lipophilicity and basal tissue concentrations of AA, compared with its P450 metabolites.
Very recently [24], an LC-MS/MS method was reported for the simultaneous analysis of AA and
32 related metabolites in human plasma using a conventional LC system with a run time of 30
min. However, the actual plasma concentrations of AA in the human plasma samples (1143
ng/mL) were substantially higher than the highest calibration standard (200 ng/mL) and the
highest validated QC sample (32 ng/mL) for AA. Additionally, the recovery of AA from the
samples was not reported [24]. The much higher concentrations of AA in the actual samples
relative to the calibration curve implies that the samples needed to be diluted before analysis for
quantitation of AA, requiring duplicate sample preparation or analysis. Therefore, it appears that
there is no validated LC-MS/MS method that can quantitate very high concentrations of AA
along with very low concentrations of most of its P450 metabolites in one run.
During method development process, we first tried to quantitate AA and its metabolites
simultaneously in one run by developing 1) a single sample processing method to simultaneously
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recover both AA and its metabolites quantitatively from the liver, 2) a gradient mobile phase to
elute AA and its metabolites in a reasonably short time, and 3) an MS setting to accurately
quantitate all the analytes. Although we were successful in achieving the first (Table 4) and
second (data not shown) goals, the more than 1000 fold difference in the basal concentrations of
AA and its P450 metabolites in the liver (Fig. 7) prevented accurate measurement and validation
of the analysis of all analytes in one run. Therefore, we injected each processed liver sample
twice, once undiluted for the measurement of low concentrations of AA metabolites and the
second time for the quantitation of high concentrations of AA after 4000 fold dilution of the
same processed sample. Although requiring separate injections, this method is time saving as it
only needs one sample preparation. Nevertheless, the gradient elution of AA metabolites using
our UHPLC system resulted in satisfactory resolution of all the 10 studied metabolites within 2.5
min with a total run time of 5 min (Fig. 2). Additionally, the isocratic elution of AA occurred in
< 1 min (Fig. 3) with a run time of 2 min. Therefore, the total run time for the analysis of both
AA and its metabolites separately is ~7 min, which is significantly shorter than the run time of
most of the available LC-MS/MS methods that use conventional LC systems with relatively long
columns [22, 24, 25, 32-34].
Measurement of the free concentrations of P450-mediated metabolites of AA in the liver
is challenging. First, most of these metabolites are unstable and subject to oxidation during the
sample preparation. Therefore, most methods that attempt at quantitating these metabolites add
an antioxidant such as triphenylphosphine [9] or BHT [22, 23] to the samples to prevent
oxidation during the in vitro processing of the samples before injection. Despite the addition of
antioxidants, long sample preparation procedures may result in some inaccuracies in the
determination of the actual concentrations of these metabolites, which is particularly true for the
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more labile metabolites, such as 5,6-EET [36]. Almost all the available methods for quantitation
of P450 metabolites of AA in biological samples use solid-phase extraction [22-24], which
requires multistep wash and elution of the samples followed by evaporation of the eluted samples
before injection. These methods at times result in low recovery of some of the metabolites of AA
[34]. Instead, our method uses a short sample preparation method consisting of direct
homogenization of the samples in methanol, followed by evaporation and injection of the
reconstituted residues. Indeed, our simple sample preparation method resulted in high recoveries
in the range of 78.8% to 90.7% for EETs, DHETs, and HETEs (Table 4). Additionally, the
recovery of the more labile 5,6-EET (80.3%) was not different from that of other EETs (Table
4). These data suggest suitability of our sample preparation method for optimal recovery and
stability of the analytes.
Another challenge in quantitation of P450 metabolites of AA in tissues is the fact that
similar to AA, most of the metabolites of AA in the tissues are also bound to phospholipids, and
only a small fraction of the metabolites in the tissue are in the form of free acids. Karara et al. [9]
showed that >90% of the rat liver EETs are present in phospholipids, mostly in the sn-2 position,
and ~8% are incorporated into the diglycerides and neutral lipids. They showed that free EETs
constitute only a negligible fraction (<1%) of the total EET pool of the liver tissue. The
phospholipid incorporation also occurs for other metabolites of AA, such as HETEs [37, 38].
The significant incorporation of AA and its P450 metabolites in the phospholipids necessitates a
sample handling method that prevents or minimizes the release of phospholipid-bound
compounds during the sample storage and preparation. Otherwise, the measured quantities may
not be a reflection of true concentrations of the free analytes in the tissue.

	
  

21	
  

With the exception of a report by Karara at al. [17], who used fresh liver samples, most
sample handling methods reported in the literature use frozen samples for the analysis of AA and
its metabolites [21, 22]. We also initially used pulverized liver samples, which were prepared
after snap freezing the liver tissue immediately after collection. The pulverized samples were
then used for homogenization. However, this procedure resulted in substantial variability in the
measured concentrations of the analytes from the same liver sample. Therefore, we tested the
effects of sample handling on the liver concentrations of AA and its metabolites, which showed
that freeze-thaw of the samples substantially (up to 120 fold) increases the concentrations of AA
and all of its studied metabolites, relative to the fresh liver samples (Fig. 4). The freeze-thawinduced substantial increases in the concentrations of analytes suggest destabilization of
phospholipids and release of AA and its metabolites from these storage sites. These results
clearly show that for accurate estimation of free AA and its metabolites in tissue samples, the
tissues must be processed immediately after collection without freezing.
Although the P450-mediated metabolites of AA may potentially play a significant role in
the pathophysiology of some liver diseases [15, 39, 40], we are aware of only one study that
reported the free concentrations of EETs in the liver [9]. Using fresh livers and a GC/MS
method, these authors reported a liver concentration of 2 ng/g for EETs as free acids. However,
the concentrations of individual regioisomers of EET or other P450 mediated metabolites of AA
were not reported. Others [41] have reported the liver concentrations of 8,9-, 11,12-, and 14,15DHET and 20-HETE in rats after LC/MS analysis of frozen liver samples, but were unable to
detect the liver concentrations of EETs. Therefore, our study appears to be the first report of the
free concentrations of the individual regioisomers of EET and DHET, in addition to 19- and 20HETE, in the liver tissue.
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In contrast to the paucity of data for the free concentrations of AA metabolites in the liver
tissue, few reports exist that describe the total (free plus membrane bound) concentrations of
some of the P450-mediated metabolites of AA in the liver after saponification. Using GC/MS,
Karara et al. [17] reported the total concentrations of 8,9-, 11,12-, and 14,15-EET in the liver of
rats. However, because of its lability, the concentration of 5,6-EET was not reported. These
authors showed that the rat liver contains ~ 0.8 µg of EET/g of tissue, which is in agreement with
another report from the same group [9]. In another study using a combination of HPLC and
GC/MS, Zeldin et al. [42] reported that the total concentrations of 8,9-, 11,12-, and 14,15-EET in
the human liver tissue were 73, 113, and 197 ng/g, respectively. They were also able to
quantitate all the four regioisomers of DHETs in the liver [42]. Although informative, the total
concentrations of EETs may not reflect subtle temporal changes in different pathophysiologic
conditions, which may affect the free concentrations of these metabolites.
The application of the assay to the measurement of AA and its metabolites (Fig. 7)
indicated that partial liver ischemia significantly increases the free concentrations of AA and all
of the measured metabolites except for 20-HETE. The ischemia-induced significant increase in
the concentrations of AA (Fig. 7A) is most likely due to its release from the membrane storage
sites during ischemia. The ischemia-induced increase in the concentrations of the metabolites of
AA could potentially be due to higher formation of the metabolites, because of the availability of
more substrate (AA), and/or a simultaneous release of the preformed metabolites from their
storage sites. Because our model consisted of 1 h ischemia without any reperfusion, a significant
contribution of metabolism of the released AA to the metabolites is unlikely. Therefore, the
observed higher concentrations of the metabolites in ischemic livers is most likely due to their
release from their storage sites. Indeed, as mentioned before, both EETs [9] and HETEs [37, 38]
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are incorporated into the rat liver phospholipids and are released from these sites by the action of
phospholipases [9, 10]. Furthermore, the activity and/or concentration of phospholipases are
expected to increase as a result of ischemic injury [43, 44], potentially releasing the metabolites
from their storage sites. Nevertheless, further studies are needed to determine the exact
mechanisms responsible for the ischemia-induced increases in the liver concentration of the AA
metabolites observed in our study (Fig. 7).
5. Conclusions
In conclusion, a rapid and sensitive UHPLC-MS/MS method was developed for the
quantitation of free concentrations of AA and its major P450 metabolites in the liver. After a
single sample preparation procedure, the processed sample is injected twice, once for the
simultaneous quantitation of all four regioisomers of EET and DHET and two major
regioisomers of HETE, in addition to their respective deuterated internal standards, and the
second time for the analysis of AA. The method was successfully applied to quantitation of the
liver concentrations of AA and its metabolites in rats subjected to partial hepatic ischemia.
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Table 1	
  
Compound parameters for arachidonic acid, its P450 metabolites, and the deuterated internal
standards with MRM in negative electrospray ionization mode.
Analyte

Q1 Mass

Q3 Mass

Da

DP

CE

CXP

EP

V

AA

303

259

-125

-18

-15

-10

AA-d8

311

267

-125

-18

-15

-10

19-HETE

319

231

-125

-20

-13

-10

20-HETE

319

245

-95

-22

-15

-10

20-HETE-d6

325

281

-110

-22

-15.5

-10

5,6-EET

319

191

-30

-14

-11

-10

8,9-EET

319

155

-30

-14

-11

-10

8,9-EET-d11

330

155

-25

-18

-19

-10

11,12-EET

319

208

-120

-16

-13

-10

14,15-EET

319

219

-105

-16

-13

-10

14,15-EET-d11

330

268

-120

-18

-15

-10

5,6-DHET

337

145

-115

-22

-11

-10

8,9-DHET

337

127

-105

-26

-11

-10

11,12-DHET

337

167

-115

-24

-19

-10

14,15-DHET

337

207

-40

-24

-13

-10

14,15-DHET-d11

348

207

-95

-24

-13

-10

Abbreviations: DP, declustering potential; CE, collision energy; CXP, collision cell exit
potential; EP, entrance potential
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Table 2
Representative linear equations for the standard curves of arachidonic acid and
its P450 metabolites prepared in ethanol.
Analyte

Linear equation

AA

y = 0.04540 x + 0.05112

19-HETE

y = 0.03078 x – 0.00172

20-HETE

y = 0.02810 x + 0.00345

5,6-EET

y = 0.17962 x – 7.87085e-4

8,9-EET

y = 0.11991 x – 0.00340

11,12-EET

y = 0.07174 x – 0.00275

14,15-EET

y = 0.18711 x + 0.00151

5,6-DHET

y = 0.00575 x – 7.81621e-5

8,9-DHET

y = 0.00393 x – 2.02197e-4

11,12-DHET

y = 0.01106 x – 4.33385e-4

14,15-DHET

y = 0.00870 x – 7.74597e-5

y: peak area ratio; x: analyte concentration in ng/mL except for AA, which was
µg/mL.
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Table 3
Intra- and inter-run accuracy and precision of the method using samples prepared in ethanol (n = 5).
Intra-run
Inter-run
Concentration
Accuracy
R.S.D. (%)
Accuracy
R.S.D. (%)
AA (µg/mL)
7.81
62.5
500
19-HETE (ng/mL)
0.94
3.75
30
20-HETE (ng/mL)
0.94
3.75
30
5, 6-EET (ng/mL)
0.38
1.5
12
8,9-EET (ng/mL)
0.75
3.0
24
11,12-EET (ng/mL)
0.38
1.5
12
14,15-EET (ng/mL)
0.38
1.5
12
5,6-DHET (ng/mL)
0.19
1.5
12
8,9-DHET (ng/mL)
0.38
3.0
24
11,12-DHET (ng/mL)
0.48
3.75
30
14,15-DHET (ng/mL)
1.88
15
120

	
  

97.4
104
93.3

14.3
2.00
2.34

90.1
106
90.5

15.6
8.35
5.03

85.6
100
97.2

10.7
2.31
4.29

110
94.1
97.8

10.4
8.12
4.17

95.1
102
95.2

6.02
10.3
3.13

98.8
105
100

13.7
5.66
5.18

81.6
100
98.4

10.7
2.41
3.33

83.6
99.3
102

19.3
6.13
3.10

96.0
95.9
99.1

19.3
8.56
2.86

99.9
98.6
99.7

10.9
5.25
2.59

99.1
102
92.4

3.49
3.06
3.13

111
100
100

8.87
5.63
3.14

99.3
94.7
92.5

14.0
7.47
3.31

94.7
96.6
101

13.4
9.64
2.67

98.6
97.6
97.6

11.6
1.69
2.61

97.8
98.1
100

10.6
3.16
2.02

100
98.2
96.8

7.93
2.48
4.84

94.7
93.0
99.9

9.21
7.87
1.4

106
101
98.5

3.51
3.12
3.22

98.6
98.3
100

3.24
2.97
1.31

87.9
106
95.8

1.94
2.72
2.44

86.5
102
97.1

5.56
3.48
1.63
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Table 4	
  
Recovery and matrix factor (mean ± S.D.) of AA, its P450
metabolites, and internal standards using liver homogenates (n = 6).
Analyte

% Recovery

Matrix factor

AA

87.5 ± 4.1

83.7 ± 14.6

AA-d8

87.7 ± 3.5

92.3 ± 6.0

19-HETE

90.7 ± 2.9

90.0 ± 2.8

20-HETE

88.9 ± 4.6

91.9 ± 3.6

20-HETE-d6

92.1 ± 5.0

91.2 ± 6.3

5,6-EET

80.3 ± 7.4

88.7 ± 1.5

8,9-EET

78.8 ± 6.6

82.5 ± 3.2

8,9-EET-d11

80.0 ± 6.8

77.0 ± 3.1

11,12-EET

80.4 ± 6.8

77.1 ± 2.1

14,15-EET

82.5 ± 5.6

94.6 ± 1.4

14,15-EET-d11

83.5 ± 5.1

95.5 ± 2.2

5,6-DHET

87.0 ± 3.7

92.8 ± 2.2

8,9-DHET

88.9 ± 3.5

85.5 ± 1.4

11,12-DHET

87.8 ± 5.8

92.0 ± 1.9

14,15-DHET
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Legend for Figures
Fig. 1. Chemical structures of arachidonic acid and its metabolites that were analyzed in this
study.
Fig. 2. Representative chromatograms of DHETs (Panel A), HETEs (Panel B), EETs (Panel C),
and their internal standards (Panel D). The peaks correspond to 3 µL of sample injected into the
instrument. The analyte concentrations in the samples were 30 ng/mL of 19-HETE, 20-HETE,
and 11,12-DHET; 24 ng/mL of 8,9-EET and 8,9-DHET; 12 ng/mL of 5,6-EET, 11,12-EET,
14,15-EET, and 5,6-DHET; 120 ng/mL of 14,15-DHET; 30 ng/mL of 20-HETE-d6; 25 ng/mL of
8,9-EET-d11 and 14,15-EET-d11; and 60 ng/mL of 14,15-DHET-d11. 	
  
Fig. 3. Representative chromatograms of AA and its internal standard (AA-d8) in a sample
containing 500 µg/mL of AA and 70 µg/mL of AA-d8. The sample was diluted 4000 fold before
injection.
Fig. 4. The effects of storage of fresh livers on ice for 0 (Fresh-0), 20 (Fresh-20), 40 (Fresh-40),
or 60 (Fresh-60) min and sample freeze-thaw on the liver concentrations of AA and its
metabolites. Columns and bars represent mean and S.D. values, respectively (n = 3). *, P < 0.05;
**, P < 0.01; ***, P < 0.001: Significantly different from the Fresh-0 sample, based on one-way
ANOVA, followed by post-hoc analysis using Dunnett’s multiple comparison test.
Fig. 5. Effects of storage of methanolic extracts of fresh liver samples at 80oC on the
concentrations of AA and its metabolites. Columns and bars represent mean and S.D. values,
respectively (n = 6). *, P < 0.05; **, P < 0.01: Significantly different from the baseline
concentration based on repeated measures one-way ANOVA, followed by post-hoc analysis
using Dunnett’s multiple comparison test.
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Fig. 6. Absolute peak areas of the analytes and internal standards after storage (4oC) of the final
processed samples in the autosampler for up to 5 h. Columns and bars represent mean and S.D.
values, respectively (n = 4). There were no statistical differences among the groups tested by
repeated measure one-way ANOVA.
Fig. 7. The concentrations of arachidonic acid (A), 19- and 20-HETE (B), 5,6-, 8,9-, 11,12-, and
14,15-EET (C), 5,6-, 8,9-, 11,12-, and 14,15-DHET (D) in the liver samples from Sham and
Ischemia rats. The columns and bars represent mean and S.D. values, respectively (n = 6). *, P <
0.05; **, P < 0.01: Significantly different from the Sham group, based on unpaired, two-tailed t
test with Welch’s correction.
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